Author

O. Tarasova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Inga· 1 shared A. Karlen· 1 shared A. L. Okorokov· 1 shared A. Vema· 1 shared C. Spinnler· 1 shared D. Filimonov· 1 shared E. Hedstrom· 1 shared E. R. Dickinson· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Inga

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Comprehensive analysis of HIV elite controllers and progressors' transcriptional profiles from CD8+ T lymphocytes demonstrates heterogeneity of pathways and master regulators, which may be essential for disease nonprogression

S. Ivanov, D. Filimonov, O. Tarasova

The paper identifies distinct transcriptional groups in HIV elite controllers and progressors, revealing pathway heterogeneity and potential master regulators associated with nonprogression.

bioRxiv · Oct 19, 2020 · PreprintMicrobiology

Novel allosteric mechanism of p53 activation by small molecules for targeted anticancer therapy

J. Zawacka-Pankau, V. V. Grinkevich, M. Burmakin, A. Vema, K. Fawkner, N. Issaeva, V. Andreotti, E. R. Dickinson, E. Hedstrom, C. Spinnler, A. Inga, L.-G. Larsson, A. Karlen, O. Tarasova, V. Poroikov, , G. Selivanova

This study identifies a novel allosteric mechanism by which small molecules activate p53 by blocking MDM2/MDMX binding, offering a new approach for anticancer therapy.

bioRxiv · Dec 7, 2018 · PreprintCancer Biology